Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1970 1
1974 1
1975 1
1979 2
1980 1
1981 2
1983 1
1984 3
1985 1
1986 1
1987 3
1989 1
1990 6
1991 3
1992 5
1993 7
1994 2
1995 8
1996 3
1997 9
1998 5
1999 9
2000 8
2001 12
2002 12
2003 15
2004 24
2005 27
2006 33
2007 28
2008 31
2009 28
2010 27
2011 34
2012 41
2013 50
2014 58
2015 67
2016 89
2017 86
2018 61
2019 92
2020 75
2021 91
2022 88
2023 92
2024 27

Text availability

Article attribute

Article type

Publication date

Search Results

1,136 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean c cost[Author] (36 results)?
Machine learning-aided engineering of hydrolases for PET depolymerization.
Lu H, Diaz DJ, Czarnecki NJ, Zhu C, Kim W, Shroff R, Acosta DJ, Alexander BR, Cole HO, Zhang Y, Lynd NA, Ellington AD, Alper HS. Lu H, et al. Among authors: acosta dj. Nature. 2022 Apr;604(7907):662-667. doi: 10.1038/s41586-022-04599-z. Epub 2022 Apr 27. Nature. 2022. PMID: 35478237
Our mutant and scaffold combination (FAST-PETase: functional, active, stable and tolerant PETase) contains five mutations compared to wild-type PETase (N233K/R224Q/S121E from prediction and D186H/R280A from scaffold) and shows superior PET-hydrolytic activity relative to both wil …
Our mutant and scaffold combination (FAST-PETase: functional, active, stable and tolerant PETase) contains five mutations compared to wild-t …
36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016.
Bateman RM, Sharpe MD, Jagger JE, Ellis CG, Solé-Violán J, López-Rodríguez M, Herrera-Ramos E, Ruíz-Hernández J, Borderías L, Horcajada J, González-Quevedo N, Rajas O, Briones M, Rodríguez de Castro F, Rodríguez Gallego C, Esen F, Orhun G, Ergin Ozcan P, Senturk E, Ugur Yilmaz C, Orhan N, Arican N, Kaya M, Kucukerden M, Giris M, Akcan U, Bilgic Gazioglu S, Tuzun E, Riff R, Naamani O, Douvdevani A, Takegawa R, Yoshida H, Hirose T, Yamamoto N, Hagiya H, Ojima M, Akeda Y, Tasaki O, Tomono K, Shimazu T, Ono S, Kubo T, Suda S, Ueno T, Ikeda T, Hirose T, Ogura H, Takahashi H, Ojima M, Kang J, Nakamura Y, Kojima T, Shimazu T, Ikeda T, Suda S, Izutani Y, Ueno T, Ono S, Taniguchi T, O M, Dinter C, Lotz J, Eilers B, Wissmann C, Lott R, Meili MM, Schuetz PS, Hawa H, Sharshir M, Aburageila M, Salahuddin N, Chantziara V, Georgiou S, Tsimogianni A, Alexandropoulos P, Vassi A, Lagiou F, Valta M, Micha G, Chinou E, Michaloudis G, Kodaira A, Ikeda T, Ono S, Ueno T, Suda S, Izutani Y, Imaizumi H, De la Torre-Prados MV, Garcia-De la Torre A, Enguix-Armada A, Puerto-Morlan A, Perez-Valero V, Garcia-Alcantara A, Bolton N, Dudziak J, Bonney S, Tridente A, Nee P, Nicolaes G, Wiewel M, Schultz M, Wildhag… See abstract for full author list ➔ Bateman RM, et al. Among authors: acosta j. Crit Care. 2016 Apr 20;20(Suppl 2):94. doi: 10.1186/s13054-016-1208-6. Crit Care. 2016. PMID: 27885969 Free PMC article.
Bhandari P221 - Setting optimal flow rate during high flow nasal cannula support: preliminary results T. Mauri, C. Turrini, T. Langer, P. Taccone, C. A. Volta, C. Marenghi, L. ...Loveridge, C. Chaddock, S. Patel, V. Kakar, C. Willars, T. Hurst, …
Bhandari P221 - Setting optimal flow rate during high flow nasal cannula support: preliminary results T. Mauri, C. Turrini, T. Langer …
Tetra-aqua-bis-(2,3-di-hydro-1,4-benzodioxine-2-carboxyl-ato)calcium(II).
Camargo-Cortés EB, Acosta M, Martínez JC, Pineda LW. Camargo-Cortés EB, et al. Among authors: acosta m. IUCrdata. 2020 Aug 14;5(Pt 8):x201092. doi: 10.1107/S2414314620010925. eCollection 2020 Aug. IUCrdata. 2020. PMID: 36338513 Free PMC article.
The acid-base reaction of 1,4-benzodioxane 2-carb-oxy-lic acid with calcium carbonate furnished the centrosymmetric title compound, [Ca(C(9)H(7)O(4))(2)(H(2)O)(4)], in which the metal ion is octa-hedrally coordinated by two monodentate 1,4-benzodioxane 2-carboxyl-ate ligan …
The acid-base reaction of 1,4-benzodioxane 2-carb-oxy-lic acid with calcium carbonate furnished the centrosymmetric title compound, [Ca(C …
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
Rozeman EA, Menzies AM, van Akkooi ACJ, Adhikari C, Bierman C, van de Wiel BA, Scolyer RA, Krijgsman O, Sikorska K, Eriksson H, Broeks A, van Thienen JV, Guminski AD, Acosta AT, Ter Meulen S, Koenen AM, Bosch LJW, Shannon K, Pronk LM, Gonzalez M, Ch'ng S, Grijpink-Ongering LG, Stretch J, Heijmink S, van Tinteren H, Haanen JBAG, Nieweg OE, Klop WMC, Zuur CL, Saw RPM, van Houdt WJ, Peeper DS, Spillane AJ, Hansson J, Schumacher TN, Long GV, Blank CU. Rozeman EA, et al. Among authors: acosta at. Lancet Oncol. 2019 Jul;20(7):948-960. doi: 10.1016/S1470-2045(19)30151-2. Epub 2019 May 31. Lancet Oncol. 2019. PMID: 31160251 Clinical Trial.
Within the first 12 weeks, grade 3-4 immune-related adverse events were observed in 12 (40%) of 30 patients in group A, six (20%) of 30 in group B, and 13 (50%) of 26 in group C. The difference in grade 3-4 toxicity between group B and A was -20% (95% CI -46 to 6; p=0.158) …
Within the first 12 weeks, grade 3-4 immune-related adverse events were observed in 12 (40%) of 30 patients in group A, six (20%) of 30 in g …
MYC sensitises cells to apoptosis by driving energetic demand.
Edwards-Hicks J, Su H, Mangolini M, Yoneten KK, Wills J, Rodriguez-Blanco G, Young C, Cho K, Barker H, Muir M, Guerrieri AN, Li XF, White R, Manasterski P, Mandrou E, Wills K, Chen J, Abraham E, Sateri K, Qian BZ, Bankhead P, Arends M, Gammoh N, von Kriegsheim A, Patti GJ, Sims AH, Acosta JC, Brunton V, Kranc KR, Christophorou M, Pearce EL, Ringshausen I, Finch AJ. Edwards-Hicks J, et al. Among authors: acosta jc. Nat Commun. 2022 Aug 9;13(1):4674. doi: 10.1038/s41467-022-32368-z. Nat Commun. 2022. PMID: 35945217 Free PMC article.
Clinical and genomic characterisation of early-onset pancreatic cancer.
Castet F, Fabregat-Franco C, Castillo G, Navarro V, Sierra A, Acosta DA, López-Valbuena D, Dienstmann R, Tabernero J, Vivancos A, Tian TV, Macarulla T. Castet F, et al. Among authors: acosta da. Eur J Cancer. 2023 Nov;194:113338. doi: 10.1016/j.ejca.2023.113338. Epub 2023 Sep 9. Eur J Cancer. 2023. PMID: 37793216
Ultrastructural and biochemical basis for hepatitis C virus morphogenesis.
Falcón V, Acosta-Rivero N, González S, Dueñas-Carrera S, Martinez-Donato G, Menéndez I, Garateix R, Silva JA, Acosta E, Kourı J. Falcón V, et al. Among authors: acosta e. Virus Genes. 2017 Apr;53(2):151-164. doi: 10.1007/s11262-017-1426-2. Epub 2017 Feb 23. Virus Genes. 2017. PMID: 28233195 Review.
Genetic markers for preeclampsia in Peruvian women.
Pacheco-Romero J, Acosta O, Huerta D, Cabrera S, Vargas M, Mascaro P, Huamán M, Sandoval J, López R, Mateus J, Gil E, Guevara E, Butrica N, Catari D, Bellido D, Custodio G, Naranjo A. Pacheco-Romero J, et al. Among authors: acosta o. Colomb Med (Cali). 2021 Feb 26;52(1):e2014437. doi: 10.25100/cm.v52i1.4437. Colomb Med (Cali). 2021. PMID: 33911318 Free PMC article.
OBJECTIVE: To determine the association of the vascular endothelial growth factor (VEGF) +936 C/T and +405 G/C, interleukine-6 (IL-6) -174 G/C, IL-1beta-511 C/T, Apo A-1-75 G/A, Apo B-100 2488 C/T (Xbal) polymorphisms with preeclampsia in pregna …
OBJECTIVE: To determine the association of the vascular endothelial growth factor (VEGF) +936 C/T and +405 G/C, interleukine-6 …
Senescence: a new weapon for cancer therapy.
Acosta JC, Gil J. Acosta JC, et al. Trends Cell Biol. 2012 Apr;22(4):211-9. doi: 10.1016/j.tcb.2011.11.006. Epub 2012 Jan 13. Trends Cell Biol. 2012. PMID: 22245068 Review.
In recent years, therapeutic approaches such as p53 reactivation, inhibition of c-MYC in addicted tumors or treatment with cyclin-dependent kinase (CDK) inhibitors have proven effective by invoking a senescence response. ...
In recent years, therapeutic approaches such as p53 reactivation, inhibition of c-MYC in addicted tumors or treatment with cyclin-dep …
Genetically Determined Low-Density Lipoprotein Cholesterol and Risk of Subarachnoid Hemorrhage.
Acosta JN, Both CP, Szejko N, Leasure AC, Abdelhakim S, Torres-Lopez VM, Brown SC, Matouk CC, Gunel M, Sheth KN, Falcone GJ. Acosta JN, et al. Ann Neurol. 2022 Jan;91(1):145-149. doi: 10.1002/ana.26250. Epub 2021 Nov 1. Ann Neurol. 2022. PMID: 34709661
In secondary analyses, we implemented the MR-PRESSO method, restricted our analysis to LDL-C-specific instruments, and performed multivariate MR. A 1-mmol/l increase in genetically instrumented LDL-C levels was associated with a 17% lower risk of IA/SAH (odds ratio …
In secondary analyses, we implemented the MR-PRESSO method, restricted our analysis to LDL-C-specific instruments, and performed mult …
1,136 results